Literature DB >> 17827048

Owners 'perception of their cats' quality of life during COP chemotherapy for lymphoma.

Sophia Tzannes1, Margaret F Hammond, Suzanne Murphy, Andrew Sparkes, Laura Blackwood.   

Abstract

Questionnaires regarding the perceptions of chemotherapy and its impact on the quality of life (QoL) of their cat were received from owners of 31 cats treated for lymphoma between 2002 and 2006 with COP (cyclophosphamide, vincristine, prednisolone) chemotherapy. The QoL scores prior to the onset of cancer (mean 9.5, range 6-10) were significantly higher than the ratings given after the onset of cancer but before commencement of chemotherapy (mean 3.9, range 1-9.4). The QoL scores during chemotherapy (mean 6.3, range 1-10) were also significantly lower than prior to the onset of cancer, but significantly higher during treatment than prior to starting treatment. Adverse effects were experienced by 27 (87%) cats during the course of chemotherapy. Twenty-five (83%) of clients were happy they treated their cat and 27 owners (87%) would treat another cat. The results suggest that COP chemotherapy is perceived by owners to be tolerated by cats.

Entities:  

Mesh:

Year:  2007        PMID: 17827048     DOI: 10.1016/j.jfms.2007.05.008

Source DB:  PubMed          Journal:  J Feline Med Surg        ISSN: 1098-612X            Impact factor:   2.015


  10 in total

1.  Factors Which Influence Owners When Deciding to Use Chemotherapy in Terminally Ill Pets.

Authors:  Jane Williams; Catherine Phillips; Hollie Marie Byrd
Journal:  Animals (Basel)       Date:  2017-03-07       Impact factor: 2.752

2.  Health-related quality of life in dogs treated with electrochemotherapy and/or interleukin-12 gene electrotransfer.

Authors:  Nina Milevoj; Natasa Tozon; Sabina Licen; Ursa Lampreht Tratar; Gregor Sersa; Maja Cemazar
Journal:  Vet Med Sci       Date:  2020-01-07

3.  A Preliminary Description of Companion Cat, Managed Stray Cat, and Unmanaged Stray Cat Welfare in Auckland, New Zealand Using a 5-Component Assessment Scale.

Authors:  Sarah Zito; Jessica Walker; M Carolyn Gates; Arnja Dale
Journal:  Front Vet Sci       Date:  2019-02-21

4.  Assessment of compounded transdermal mirtazapine as an appetite stimulant in cats with chronic kidney disease.

Authors:  Jessica M Quimby; Kellyi K Benson; Stacie C Summers; Ashlie Saffire; Andrea K Herndon; Shasha Bai; Daniel L Gustafson
Journal:  J Feline Med Surg       Date:  2019-06-04       Impact factor: 2.015

5.  Quality of life assessment in cancer patients receiving single-agent versus multidrug chemotherapy protocols.

Authors:  Marco Luigi Bianchi; Dario Drudi; Elisabetta Treggiari; Chiara Catalucci; Valeria Attorri; Irene Bonazzi; Paola Valenti
Journal:  Open Vet J       Date:  2021-12-05

Review 6.  Quality of Life Measurement in Dogs and Cats: A Scoping Review of Generic Tools.

Authors:  Annabelle E Fulmer; Linda J Laven; Kate E Hill
Journal:  Animals (Basel)       Date:  2022-02-08       Impact factor: 2.752

Review 7.  Quality of life measurement in prospective studies of cancer treatments in dogs and cats.

Authors:  M A Giuffrida; S M Kerrigan
Journal:  J Vet Intern Med       Date:  2014-10-10       Impact factor: 3.333

8.  Psychometric Validation of a General Health Quality of Life Tool for Cats Used to Compare Healthy Cats and Cats with Chronic Kidney Disease.

Authors:  E S Bijsmans; R E Jepson; H M Syme; J Elliott; S J M Niessen
Journal:  J Vet Intern Med       Date:  2015-11-14       Impact factor: 3.333

9.  Aetiology and outcome in 90 cats presenting with dyspnoea in a referral population.

Authors:  S Swift; J Dukes-McEwan; S Fonfara; J F Loureiro; R Burrow
Journal:  J Small Anim Pract       Date:  2009-09       Impact factor: 1.522

10.  Appetite Stimulant and Anti-Emetic Effect of Mirtazapine Transdermal Ointment in Cats Affected by Lymphoma Following Chemotherapy Administration: A Multi-Centre Retrospective Study.

Authors:  Livia Ferro; Stefano Ciccarelli; Giacomo Stanzani; Lisa Nappi; Francesca Angelini; Chiara Leo
Journal:  Animals (Basel)       Date:  2022-01-09       Impact factor: 2.752

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.